The article discusses the role of Osimertinib as First-Line Treatment of Advanced Non-small-cell lung carcinoma (NSCLC) with epidermal growth factor receptor Mutation. Topics include showing a survival improvement over another Tyrosine kinase inhibitors (TKIs) in NSCLC; and penetrating the blood–brain barrier.